Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02494778) enrolled 248 people who received pridopidine at a dose of 45 mg twice daily. Of those who started, 27 completed the study and 221 did not complete it. The trial ran for up to 106 weeks and was measuring, among other things, any unwanted or unexpected health events (called adverse events) that participants experienced, as well as changes in certain motor (movement) functions measured using specialised sensors on the hands. The reported data shows that out of 248 participants, 193 experienced at least one adverse event over the course of the study. It is important to note that this number alone does not indicate whether those events were serious or minor — only that they were recorded and reported. For the movement measurements, the reported data shows a change from baseline (the starting point) of 0.0 and −0.1 seconds for one hand movement measure (how consistently hand rotation movements started), and changes of −2.9% and −5.9% for another measure (relating to the peak force of hand rotation movements). In these scales, a positive number would indicate worsening, so the reported figures suggest little to no change or a slight movement in the other direction, though the data does not include enough detail to draw firm conclusions. It is worth noting that the data as submitted does not include a comparison group (such as a placebo group), which limits what can be understood from these numbers on their own. Some figures, such as the timepoints for the two measurements in each motor outcome, were not clearly labelled in the reported data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 30572891) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Huntington's Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have recently completed the PRIDE HD trial (within the last 6 months, including a 2-week follow-up period), or you previously took part in the Open HART study, or you have finished another future safety and efficacy trial of the drug pridopidine
- You may also be able to re-join if you previously completed your set study period under the Open PRIDE HD trial and stopped taking pridopidine
- If you are a woman who could become pregnant, or a male participant, you must be using adequate contraception and birth control
- You are in generally good health
- Other criteria may also apply — please contact the trial site directly for full details
Who may not be able to join:
- You have certain results from heart tests (ECG), blood pressure/pulse checks, heart health assessments, or kidney function tests that fall outside acceptable ranges (similar restrictions to the PRIDE HD trial — confirm with trial site)
- You are currently taking certain other medications that are not permitted in this trial (similar restrictions to the PRIDE HD trial — confirm with trial site)
- Other exclusion criteria may also apply — please contact the trial site directly for full details
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Teva Medical Expert, MD, Teva Pharmaceuticals USA
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.